Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Cancer Vaccine Partnering Terms and Agreements

December 6, 2013

MUMBAI, India, December 6, 2013 /PRNewswire/ –

Bharat Book Bureau presents Cancer Vaccine Partnering Terms and Agreements. This
report provides an understanding and access to the cancer vaccine partnering deals and
agreements entered into by the world’s leading healthcare companies. (

http://www.bharatbook.com/healthcare-market-research-reports/cancer-vaccine-partnering-terms-and-agreements.html

)

        - Trends in cancer vaccine partnering deals
        - Disclosed headlines, upfront, milestones and royalties by stage of development
        - Cancer vaccine partnering contract documents
        - Top cancer vaccine deals by value

(Logo:
http://photos.prnewswire.com/prnh/20130128/590935 )

The report provides an understanding and analysis of how and why companies enter
cancer vaccine partnering deals. The majority of deals are discovery or development stage
whereby the licensee obtains a right or an option right to license the licensors vaccine
technology. These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms
provides critical insight into the negotiation process in terms of what you can expect to
achieve during the negotiation of terms. Whilst many smaller companies will be seeking
details of the payments clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases do not.

This report contains over 200 links to online copies of actual cancer vaccine deals
and where available, contract documents as submitted to the Securities Exchange Commission
by companies and their partners. Contract documents provide the answers to numerous
questions about a prospective partner’s flexibility on a wide range of important issues,
many of which will have a significant impact on each party’s ability to derive value from
the deal.

The initial chapters of this report provide an orientation of cancer vaccine deal
making and business activities.

Chapter 1: Provides an introduction to the report, whilst

Chapter 2: Provides an overview of the trends in cancer vaccine deal making since
2007, including details of average headline, upfront, milestone and royalty terms.It also
provides the number of deals entered by top 50 big Parma, big biotech and most active
dealmakers in cabcer vaccine partnering.

Chapter 3: Provides a review of the leading cancer vaccine deals since 2007. Deals are
listed by headline value, signed by big Parma and big biotech. Where the deal has an
agreement contract published at the SEC a link provides online access to the contract.

Chapter 4: Provides a comprehensive and detailed review of cancer vaccine partnering
deals signed and announced since January 2007, where a contract document is available in
the public domain. The chapter is organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy
focus. Each deal title links via Web link to an online version of the deal record and
where available, the contract document, providing easy access to each contract document on
demand.

The report also includes numerous tables and figures that illustrate the trends and
activities in cancer vaccine partnering and deal making since 2007. This report comes with
an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z,
deal type and stage of development.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an
in-depth understanding and access to cancer vaccine trends and structure of deals entered
into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

        - Trends in cancer vaccine deal making in the biopharma industry since 2007
        - Analysis of cancer vaccine deal structure
        - Access to headline, upfront, milestone and royalty data
        - Access to over 200 cancer vaccine deal records
        - The leading cancer vaccine deals by value since 2007
        - Includes adjuvant and drug delivery deals and alliances since 2007

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

        - Company A-Z
        - Headline value
        - Stage of development at signing
        - Deal component type
        - Specific oncology therapy target

Each deal title links via We blink to an online version of the deal record and where
available, the contract document, providing easy access to each contract document on
demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to
available deals and contract documents for over 500 cancer vaccine deals. Analyzing actual
contract agreements allows assessment of the following:

        - What are the precise rights granted or optioned?
        - What is actually granted by the agreement to the partner company?
        - What exclusivity is granted?
        - What is the payment structure for the deal?
        - How are sales and payments audited?
        - What is the deal term?
        - How are the key terms of the agreement defined?
        - How are IPRs handled and owned?
        - Who is responsible for commercialization?
        - Who is responsible for development, supply, and manufacture?
        - How is confidentiality and publication managed?
        - How are disputes to be resolved?
        - Under what conditions can the deal are terminated?
        - What happens when there is a change of ownership?
        - What sublicensing and subcontracting provisions have been agreed?
        - Which boilerplate clauses does the company insist upon?
        - Which boilerplate clauses appear to differ from partner to partner or deal
          type to deal type?
        - Which jurisdiction does the company insist upon for agreement law?

Benefits
Cancer Vaccine Partnering Agreements provides the reader with the following key benefits:

        - In-depth understanding of cancer vaccine deal trends since 2007
        - Access to headline, upfront, milestone and royalty data
        - Access to the structure of cancer vaccine agreements with numerous real life
          case studies
        - Comprehensive access to over 200 actual cancer vaccine deals entered into by
          the world's biopharma companies
        - Insight into the terms included in a cancer vaccine agreement, together with
          real world clause examples
        - Understand the key deal terms companies have agreed in previous deals
        - Undertake due diligence to assess suitability of your proposed deal terms for
          partner companies

Request for sample pages: http://www.bharatbook.com/RequestSample.asp?pid=224272

For more information on the report:

http://www.bharatbook.com/healthcare-market-research-reports/cancer-vaccine-partnering-terms-and-agreements.html

Related Reports:

        - Global Cancer Vaccines Pipeline Analysis
          [http://www.bharatbook.com/healthcare-market-research-reports/global-cancer-vaccines-pipeline-analysis.html ]
        - Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer
          Treatments and Extended Patient Survival, though High Prices May Limit Uptake
          [http://www.bharatbook.com/healthcare-market-research-reports/therapeutic-cancer-vaccines-market-to-2019-pipeline-indicates-safer-treatments-and-extended-patient-survival-though-high-prices-may-limit-uptake.html ]
        - US Cancer Vaccine Market Analysis
          [http://www.bharatbook.com/healthcare-market-research-reports/us-cancer-vaccine-market-analysis.html ]
        - Infectious Vaccines Partnering Terms and Agreements
          [http://www.bharatbook.com/healthcare-market-research-reports/infectious-vaccines-partnering-terms-and-agreements.html ]

Related Category:

        - Cancer Vaccine
          [http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Cancer+Vaccine&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik ]
        - Cancer
          [http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Cancer&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik ]
        - Biotech
          [http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Biotech&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik ]
        - Vaccine technology
          [http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Vaccine+technology&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik ]
        - Diseases
          [http://www.bharatbook.com/searchResults.asp?Keywords=&Title=Diseases&Publisher=&PublishPeriod=0&PriceFrom=&PriceTo=&RegionID=&CountryID=&Category=&SubCategory=&srchtype=qik ]

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides
market research reports, industry analysis, company profiles, business reports, country
reports, newsletters and online databases. Our clients include Corporate, Consulting
firms, and Academic Institutions and Government departments across the globe. Bharat Book
Bureau provides over a million reports from more than 400 publishers around the globe. The
market research reports we provide, help global companies examine the different markets
before setting up a business or expanding into different countries across the world. They
give a complete perspective on the current market scenario, trends, segments and future
outlook.

Contact us:

        Poonam
        Bharat Book Bureau
        USA/Canada - 1-866-279-8368 (Toll free)
        India: +91-22-27810772, 27810773
        Blog: http://blog.bharatbook.com
        E: poonam@bharatbook.com
        W: http://www.bharatbook.com


    Photo: 

http://photos.prnewswire.com/prnh/20130128/590935

SOURCE Bharat Book Bureau


Source: PR Newswire